Australian Clinical Labs Ltd(AU:ACL)
A$3.350.00 (0.00%)
AU:ACL
Australian Clinical Labs Ltd financials statements
A$3.35
At close:0.00 (0.00%)
Want to see AU:ACL full AI Analyst Report?
Australian Clinical Labs Ltd (ACL) Ratios
81 Followers
Australian Clinical Labs Ltd Ratios
AU:ACL's free cash flow for Q4 2026 was AU$94.33M. For the 2026 fiscal year, AU:ACL's free cash flow was decreased by AU$-6.11M and operating cash flow was AU$100.44M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.54 | 0.55 | 0.64 | 0.62 | 0.63 |
| Quick Ratio | 0.47 | 0.48 | 0.56 | 0.54 | 0.55 |
| Cash Ratio | 0.12 | 0.10 | 0.13 | 0.11 | 0.12 |
| Solvency Ratio | 0.36 | 0.42 | 0.37 | 0.39 | 0.72 |
| Operating Cash Flow Ratio | 0.78 | 0.84 | 0.77 | 0.76 | 1.26 |
| Short-Term Operating Cash Flow Coverage | 1.51 | 0.00 | 0.00 | 0.00 | -2.91 |
| Net Current Asset Value | AU$ -329.97M | AU$ -282.79M | AU$ -281.69M | AU$ -290.28M | AU$ -252.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.57 | 0.51 | 0.52 | 0.55 | 0.42 |
| Debt-to-Equity Ratio | 2.26 | 1.69 | 1.74 | 1.83 | 1.13 |
| Debt-to-Capital Ratio | 0.69 | 0.63 | 0.64 | 0.65 | 0.53 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.20 | 0.24 | 0.28 | 0.00 |
| Financial Leverage Ratio | 3.96 | 3.35 | 3.34 | 3.36 | 2.70 |
| Debt Service Coverage Ratio | 1.45 | 10.27 | 9.24 | 12.45 | -3.45 |
| Interest Coverage Ratio | 3.33 | 14.75 | 3.34 | 4.04 | 22.78 |
| Debt to Market Cap | 0.40 | 0.08 | 0.11 | 0.10 | -0.11 |
| Interest Debt Per Share | 1.86 | 1.62 | 1.64 | 1.65 | 1.36 |
| Net Debt to EBITDA | 1.59 | 1.32 | 1.67 | 1.60 | 0.63 |
| Profitability Margins | |||||
| Gross Profit Margin | 20.59% | 36.54% | 20.07% | 81.78% | 79.02% |
| EBIT Margin | 8.43% | 9.17% | 5.98% | 8.98% | 26.95% |
| EBITDA Margin | 26.98% | 27.53% | 24.60% | 26.72% | 37.68% |
| Operating Profit Margin | 8.43% | 36.54% | 8.25% | 8.10% | 27.06% |
| Pretax Profit Margin | 5.13% | 6.50% | 5.27% | 6.98% | 25.77% |
| Net Profit Margin | 3.25% | 4.37% | 3.47% | 5.19% | 18.02% |
| Continuous Operations Profit Margin | 3.29% | 4.43% | 3.52% | 5.21% | 18.03% |
| Net Income Per EBT | 63.41% | 67.31% | 65.81% | 74.31% | 69.93% |
| EBT Per EBIT | 60.81% | 17.79% | 63.91% | 86.17% | 95.23% |
| Return on Assets (ROA) | 4.00% | 5.64% | 4.04% | 6.20% | 28.38% |
| Return on Equity (ROE) | 15.86% | 18.93% | 13.48% | 20.82% | 76.68% |
| Return on Capital Employed (ROCE) | 16.06% | 75.57% | 14.77% | 14.34% | 66.44% |
| Return on Invested Capital (ROIC) | 8.04% | 39.51% | 7.74% | 8.50% | 46.84% |
| Return on Tangible Assets | 5.54% | 7.92% | 5.59% | 8.68% | 38.53% |
| Earnings Yield | 5.52% | 6.13% | 4.79% | 5.20% | 19.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.82 | 10.54 | 8.47 | 9.23 | 10.86 |
| Payables Turnover | 34.65 | 22.90 | 21.05 | 7.02 | 7.84 |
| Inventory Turnover | 40.66 | 30.11 | 32.76 | 8.35 | 10.33 |
| Fixed Asset Turnover | 2.48 | 2.74 | 2.45 | 2.40 | 3.19 |
| Asset Turnover | 1.23 | 1.29 | 1.16 | 1.20 | 1.58 |
| Working Capital Turnover Ratio | -7.55 | -8.70 | -9.44 | -8.97 | -15.08 |
| Cash Conversion Cycle | 32.19 | 30.82 | 36.90 | 31.21 | 22.40 |
| Days of Sales Outstanding | 33.75 | 34.63 | 43.09 | 39.53 | 33.62 |
| Days of Inventory Outstanding | 8.98 | 12.12 | 11.14 | 43.69 | 35.32 |
| Days of Payables Outstanding | 10.53 | 15.94 | 17.34 | 52.01 | 46.54 |
| Operating Cycle | 42.72 | 46.75 | 54.23 | 83.22 | 68.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.85 | 0.96 | 0.80 | 0.72 | 1.41 |
| Free Cash Flow Per Share | 0.80 | 0.92 | 0.77 | 0.68 | 1.31 |
| Dividend Paid and CapEx Coverage Ratio | 4.78 | 5.48 | 6.03 | 1.38 | 6.25 |
| Capital Expenditure Coverage Ratio | 17.05 | 21.73 | 24.53 | 20.72 | 13.37 |
| Operating Cash Flow Coverage Ratio | 0.48 | 0.63 | 0.52 | 0.45 | 1.08 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.25 | 0.23 | 0.21 | 0.29 |
| Free Cash Flow Yield | 35.78% | 32.98% | 30.66% | 19.82% | 28.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.67 | 16.35 | 20.86 | 19.22 | 5.18 |
| Price-to-Sales (P/S) Ratio | 0.59 | 0.71 | 0.72 | 1.00 | 0.93 |
| Price-to-Book (P/B) Ratio | 2.87 | 3.09 | 2.81 | 4.00 | 3.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 2.79 | 3.03 | 3.26 | 5.05 | 3.52 |
| Price-to-Operating Cash Flow Ratio | 2.63 | 2.89 | 3.13 | 4.80 | 3.25 |
| Price-to-Earnings Growth (PEG) Ratio | -0.63 | 0.39 | -0.63 | -0.24 | 0.04 |
| Enterprise Value Multiple | 3.77 | 3.91 | 4.61 | 5.33 | 3.11 |
| Enterprise Value | 742.28M | 797.71M | 782.01M | 986.32M | 1.16B |
| EV to EBITDA | 3.77 | 3.91 | 4.61 | 5.33 | 3.11 |
| EV to Sales | 1.02 | 1.08 | 1.13 | 1.43 | 1.17 |
| EV to Free Cash Flow | 4.83 | 4.57 | 5.11 | 7.21 | 4.41 |
| EV to Operating Cash Flow | 4.55 | 4.36 | 4.90 | 6.86 | 4.08 |
| Tangible Book Value Per Share | -0.08 | 0.04 | 0.06 | 0.04 | 0.33 |
| Shareholders’ Equity Per Share | 0.78 | 0.90 | 0.89 | 0.86 | 1.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.36 | 0.32 | 0.33 | 0.25 | 0.30 |
| Revenue Per Share | 3.80 | 3.90 | 3.47 | 3.45 | 4.91 |
| Net Income Per Share | 0.12 | 0.17 | 0.12 | 0.18 | 0.89 |
| Tax Burden | 0.63 | 0.67 | 0.66 | 0.74 | 0.70 |
| Interest Burden | 0.61 | 0.71 | 0.88 | 0.78 | 0.96 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.12 | 0.44 | 0.45 | 0.43 | 0.32 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 6.89 | 5.64 | 6.67 | 4.00 | 1.59 |
Currency in AUD

